Pembrolizumab Significantly Improves Survival in Platinum-Resistant Ovarian Cancer
A study published in The Lancet shows that pembrolizumab (Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian cancer, a difficult-to-treat patient population.
·1 source
